Nicole Kuzmin-Nichols, MBA, Saneron's Senior Vice President -- Corporate Development and Operations, stated, "We are very pleased to partner with Cryo-Cell to commence pre-clinical studies necessary to advance the utilization of C'elle menstrual stem cells in developing potential therapies for debilitating neurological disorders that impact millions of lives."
Under terms of the agreement, the Company will provide C'elle menstrual stem cells along with proprietary methodology associated with the technology. Saneron will provide study materials and develop research methodology for potential therapeutic applications associated with designated pre-clinical applications. Intellectual property resulting from this research collaboration will be jointly owned by the parties. Cryo-Cell owns an approximately 38% equity interest in Saneron CCEL.
About Saneron CCEL Therapeutics, Inc.
Saneron is a biotechnology R&D company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, which is located at the Tampa Bay Technology Incubator, was a University of South Florida spin-out company and is partially owned by Cryo-Cell International, Inc. Saneron is committed to providing readily available, non-controversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.
About Cryo-Cell International, Inc.
Based in Oldsmar, Florida, with over 140,000 clients worldwide,
Cryo-Cell is one of the largest and most established family cord blood
|SOURCE Cryo-Cell International Inc.|
Copyright©2008 PR Newswire.
All rights reserved